Literature DB >> 11023514

A partial deficiency of interleukin-7R alpha is sufficient to abrogate T-cell development and cause severe combined immunodeficiency.

C M Roifman1, J Zhang, D Chitayat, N Sharfe.   

Abstract

Both in vitro and in vivo studies established that interleukin 7 (IL-7) is essential for differentiation of immature T cells and B cells but not natural killer (NK) cells in the mouse. In humans, although both T-cell and B-cell progenitors express the functional IL-7 receptor that consists of IL-7R alpha and the gamma common (gamma c) chain, this lymphocyte receptor system is critical for T lineage but not for B lineage development. Indeed, complete gamma c deficiency like IL-7R alpha deficiency results in the arrest of T-cell but not B-cell development (T(-)B(+) SCID). However, partial deficiency of gamma c caused by missense mutations results in a T(+)B(+) phenotype and a delay of clinical presentation. It was therefore plausible to assume that partial deficiency of IL-7R alpha, like partial gamma c deficiency may lead to a milder clinical and immunologic phenotype. A P132S mutation in the IL-7R alpha was identified in 3 patients with severe combined immunodeficiency (SCID) within an extensively consanguineous family. Substitution of proline with serine in the extracellular portion of IL-7R alpha did not affect IL-7R alpha messenger RNA (mRNA) and protein expression, but severely compromised affinity to IL-7, resulting in defective signal transduction. In response to IL-7 stimulation, Jak-3 phosphorylation was markedly reduced in both patient cells as well as in COS cells reconstituted with mutant IL-7R alpha. Surprisingly, this partial deficiency of IL-7R alpha resulted in a severe phenotype, including markedly reduced circulating T cells while sparing B-cell numbers similar to gamma c chain deficiency. However, unlike the previously reported cases, serum immunoglobulins were virtually absent. Further, unlike gamma c deficiency, NK cell numbers and function was preserved. Despite the partial deficiency, clinical presentation was indistinguishable from a complete gamma c deficiency, including severe and persistent viral and protozoal infections and failure to thrive. Unlike partial gamma c deficiency, a partial deficiency of IL-7R alpha results in an arrest of T-cell development, leading to typical severe combined immunodeficiency. This underscores the critical role of IL-7R alpha chain in the differentiation of T cells. (Blood. 2000;96:2803-2807)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11023514

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  IL-7 induces clathrin-mediated endocytosis of CD127 and subsequent degradation by the proteasome in primary human CD8 T cells.

Authors:  Elliott M Faller; Feras M Ghazawi; Marko Cavar; Paul A MacPherson
Journal:  Immunol Cell Biol       Date:  2015-08-14       Impact factor: 5.126

2.  Characterization of a novel nonsense mutation in the interleukin-7 receptor alpha gene in a Korean patient with severe combined immunodeficiency.

Authors:  Eun-Kyeong Jo; Hoon Kook; Toru Uchiyama; Ikuko Hakozaki; Young-Ok Kim; Chang-Hwa Song; Jeong-kyu Park; Hirokazu Kanegane; Shigeru Tsuchiya; Satoru Kumaki
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

3.  Study of the association between the CAPSL-IL7R locus and type 1 diabetes.

Authors:  J L Santiago; B Z Alizadeh; A Martínez; L Espino; H de la Calle; M Fernández-Arquero; M A Figueredo; E G de la Concha; B O Roep; B P C Koeleman; E Urcelay
Journal:  Diabetologia       Date:  2008-06-18       Impact factor: 10.122

4.  Gamma chain receptor interleukins: evidence for positive selection driving the evolution of cell-to-cell communicators in the mammalian immune system.

Authors:  Mary J O'Connell; James O McInerney
Journal:  J Mol Evol       Date:  2005-10-04       Impact factor: 2.395

5.  Genotype, phenotype, and outcomes of nine patients with T-B+NK+ SCID.

Authors:  Grace P Yu; Kari C Nadeau; David R Berk; Geneviève de Saint Basile; Nathalie Lambert; Perrine Knapnougel; Joseph Roberts; Kristina Kavanau; Elizabeth Dunn; E Richard Stiehm; David B Lewis; Dale T Umetsu; Jennifer M Puck; Morton J Cowan
Journal:  Pediatr Transplant       Date:  2011-08-23

6.  Increased CD4+ T cell levels during IL-7 administration of antiretroviral therapy-treated simian immunodeficiency virus-positive macaques are not dependent on strong proliferative responses.

Authors:  Amanda Leone; Mukta Rohankhedkar; Afam Okoye; Alfred Legasse; Michael K Axthelm; Francois Villinger; Michael Piatak; Jeffrey D Lifson; Brigitte Assouline; Michel Morre; Louis J Picker; Donald L Sodora
Journal:  J Immunol       Date:  2010-07-09       Impact factor: 5.422

7.  Functional NK cell repertoires are maintained through IL-2Rα and Fas ligand.

Authors:  Martin Felices; Todd R Lenvik; Dave E M Ankarlo; Bree Foley; Julie Curtsinger; Xianghua Luo; Bruce R Blazar; Stephen K Anderson; Jeffrey S Miller
Journal:  J Immunol       Date:  2014-03-14       Impact factor: 5.422

8.  IL-7 Dependence in human B lymphopoiesis increases during progression of ontogeny from cord blood to bone marrow.

Authors:  Yasmin Khan Parrish; Ineavely Baez; Terry-Ann Milford; Abigail Benitez; Nicholas Galloway; Jaqueline Willeman Rogerio; Eva Sahakian; Mercy Kagoda; Grace Huang; Qian-Lin Hao; Yazmar Sevilla; Lora W Barsky; Ewa Zielinska; Mary A Price; Nathan R Wall; Sinisa Dovat; Kimberly J Payne
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

9.  The dynamics of T-cell receptor repertoire diversity following thymus transplantation for DiGeorge anomaly.

Authors:  Stanca M Ciupe; Blythe H Devlin; M Louise Markert; Thomas B Kepler
Journal:  PLoS Comput Biol       Date:  2009-06-12       Impact factor: 4.475

10.  Development of a quantitative bead capture assay for soluble IL-7 receptor alpha in human plasma.

Authors:  Sylvie Faucher; Angela M Crawley; Wendy Decker; Alice Sherring; Dragica Bogdanovic; Tao Ding; Michele Bergeron; Jonathan B Angel; Paul Sandstrom
Journal:  PLoS One       Date:  2009-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.